Clarus Therapeutics Holdings, Inc. Common Stock
CRXT
CRXT was delisted on the 30th of August, 2022.
33 hedge funds and large institutions have $51M invested in Clarus Therapeutics Holdings, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 2 closing their positions.
600% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 2
57% more funds holding
Funds holding: 21 → 33 (+12)
36% more capital invested
Capital invested by funds: $37.6M → $51M (+$13.4M)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
+$2.47M |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$2.45M |
| 3 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
+$1.16M |
| 4 |
SCM
Saba Capital Management
New York
|
+$1.02M |
| 5 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$1.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$854K |
| 2 |
II
Ibex Investors
Denver,
Colorado
|
-$351K |
| 3 |
CCA
Cruiser Capital Advisors
Stamford,
Connecticut
|
-$201K |
| 4 |
MSU
Mizuho Securities USA
New York
|
-$71.8K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$17.6K |
CRXT Hedge Fund Activity: Q2 2021 in Review
33 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) for Q2 2021, worth a combined $51M — up 36% from $37.6M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new CRXT positions and 2 closed out — a net gain of 12 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Yakira Capital Management, opening a new position worth an estimated $2.47M. The largest seller was Hudson Bay Capital Management, cutting an estimated $854K.
- 33 institutional investors held Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) as of Q2 2021, up from 21 in Q1 2021.
- Funds reported $51M of Clarus Therapeutics Holdings, Inc. Common Stock stock for Q2 2021, up 36% quarter-over-quarter.
- 14 funds opened new Clarus Therapeutics Holdings, Inc. Common Stock positions in Q2 2021 and 2 closed out, a net change of +12 holders.
- The largest Clarus Therapeutics Holdings, Inc. Common Stock buyer in Q2 2021 was Yakira Capital Management, an estimated $2.47M added.
- The largest Clarus Therapeutics Holdings, Inc. Common Stock seller in Q2 2021 was Hudson Bay Capital Management, an estimated $854K sold.
Based on aggregated 13F filings for Q2 2021.